Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,798 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, Zhang W, Yang W, Li B, Fu C, Chen B, Hua L, Wang L, Luo J, Yang Y, Xu T, Wang W, Huang Y, Wu G, Liu P. Li J, et al. Among authors: bao l. Ann Hematol. 2020 Nov;99(11):2589-2598. doi: 10.1007/s00277-020-04234-9. Epub 2020 Sep 6. Ann Hematol. 2020. PMID: 32892275 Free PMC article. Clinical Trial.
[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
Yang Y, Xia ZJ, Zhang WH, Fu CC, Bao L, Chen B, Ding KY, Wang SL, Luo J, Li BZ, Hua LM, Yang W, Zhou X, Wang L, Xu TH, Wang WD, Wu GL, Huang Y, Li J, Liu P. Yang Y, et al. Among authors: bao l. Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):628-634. doi: 10.3760/cma.j.issn.0253-2727.2021.08.003. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34547867 Free PMC article. Chinese.
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China.
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, Yu H, Dong F, Liao A, Ma Y, Liu Q, Liu S, Jing H, Fu R, Ma LM, Liu H, Sun W, Bao L, Wu Y, Chen W, Zhuang J. Zhuang Z, et al. Among authors: bao l. Front Oncol. 2023 Apr 20;13:1028571. doi: 10.3389/fonc.2023.1028571. eCollection 2023. Front Oncol. 2023. PMID: 37152063 Free PMC article.
Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L, Wang YT, Liu P, Lu MQ, Zhuang JL, Zhang M, Xia ZJ, Li ZL, Yang Y, Yan ZY, Jing HM, Dong F, Chen WM, Wu Y, Zhou HB, Fu R, Gong YP, Huang WR, Zhang YQ. Bao L, et al. EClinicalMedicine. 2024 Jan 25;68:102431. doi: 10.1016/j.eclinm.2024.102431. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38318126 Free PMC article.
2,798 results